Pasar al contenido principal

REGULACION DE LA GENERACION DE TETRAPLOIDIA SOMATICA NEURONAL EN LA ENFERMEDAD DE ALZHEIMER

RTI2018-095030-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Neural network simulation with hyperploid neurons

  • Barrio-Alonso, Estíbaliz
  • Valero, Manuel
  • Fontana, Bérénice
  • Frade López, José María
This data set comprises Comma Separated Values (.CSV) files containing the results of the simulated spiking neuronal network, MATLAB variable files (.MAT) and PNG figure files. All data was obtained by the Brian2 neural network simulator. CSV file can be visualized by any text editor. MATLAB files require MATLAB or Octave. We’ve created a neuronal network composed of 4,000 neurons of three types, with different proportion of hyperploid neurons – namely, condition (from 1% to 80%) - in each of these types: (i) excitatory neurons (EXC); (ii) leading neurons (LEAD), a subtype of excitatory neurons that constitute relevant hubs of the circuit; and (iii) interneurons, with inhibitory capacity (INH). Control networks (CONTROL) did not contain hyperploid neurons. Five repetitions of each condition were simulated. All data is organized hierarchically regarding condition and repetition, and experimental folder names contains date of creation (October 2018). Estibaliz Barrio-Alonso and Manuel Valero coded the simulation and the analysis scripts. All simulations were performed under a Windows 10 machine, with Python 2.7 and MATLAB R2018a., When subjected to stress, terminally-differentiated neurons are susceptible to reactivate the cell cycle and become hyperploid. This process is well documented in Alzheimer’s disease (AD), where it may participate in the etiology of the disease. However, despite its potential importance, the effects of neuronal hyperploidy (NH) on brain function and its relationship with AD remains obscure. An important step forward in our understanding of the pathological effect of NH has been the development of transgenic mice with neuronal expression of oncogenes as model systems of AD. The analysis of these mice has demonstrated that forced cell cycle reentry in neurons results in most hallmarks of AD, including neurofibrillary tangles, Abeta peptide deposits, gliosis, cognitive loss, and neuronal death. Nevertheless, in contrast to the pathological situation, where a relatively small proportion of neurons become hyperploid, neuronal cell cycle reentry in these mice is generalized. We have recently developed an in vitro system in which cell cycle is induced in a reduced proportion of differentiated neurons, mimicking the in vivo situation. This manipulation reveals that NH correlates with synaptic dysfunction, and that membrane depolarization facilitates the survival of hyperploid neurons. This suggests that the integration of synaptically-silent, hyperploid neurons in electrically-active neural networks allows their survival while perturbing the normal functioning of the network itself, a hypothesis that we have tested in silico. To this aim, an `Integrate-and-fire´ simulation of neural networks containing hyperploid neurons was implemented using the Python-based Brian 2 simulator., This study was supported by Ministerio de Economía y Competitividad grant SAF2015-68488-R, and Ministerio de Ciencia, Innovación y Universidades grant RTI2018-095030-B-I00., See Raw Data Index.docx, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathological Aspects of Neuronal Hyperploidization in Alzheimer’s Disease Evidenced by Computer Simulation

  • Barrio-Alonso, Estíbaliz
  • Fontana, Bérénice
  • Valero, Manuel
  • Frade López, José María
When subjected to stress, terminally differentiated neurons are susceptible to reactivate the cell cycle and become hyperploid. This process is well documented in Alzheimer’s disease (AD), where it may participate in the etiology of the disease. However, despite its potential importance, the effects of neuronal hyperploidy (NH) on brain function and its relationship with AD remains obscure. An important step forward in our understanding of the pathological effect of NH has been the development of transgenic mice with neuronal expression of oncogenes as model systems of AD. The analysis of these mice has demonstrated that forced cell cycle reentry in neurons results in most hallmarks of AD, including neurofibrillary tangles, Aβ peptide deposits, gliosis, cognitive loss, and neuronal death. Nevertheless, in contrast to the pathological situation, where a relatively small proportion of neurons become hyperploid, neuronal cell cycle reentry in these mice is generalized. We have recently developed an in vitro system in which cell cycle is induced in a reduced proportion of differentiated neurons, mimicking the in vivo situation. This manipulation reveals that NH correlates with synaptic dysfunction and morphological changes in the affected neurons, and that membrane depolarization facilitates the survival of hyperploid neurons. This suggests that the integration of synaptically silent, hyperploid neurons in electrically active neural networks allows their survival while perturbing the normal functioning of the network itself, a hypothesis that we have tested in silico. In this perspective, we will discuss on these aspects trying to convince the reader that NH represents a relevant process in AD., This study was supported by Ministerio de Economía y Competitividad grant SAF2015-68488-R, and Ministerio de Ciencia, Innovación y Universidades grant RTI2018-095030- B-I00. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

E2F4-Based Gene Therapy Mitigates the Phenotype of the Alzheimer's Disease Mouse Model 5xFAD

  • López-Sánchez, Noelia
  • Garrido-García, A.
  • Ramón-Landreau, Morgan
  • Cano-Daganzo, José
  • Frade López, José María
After decades of unfruitful work, no effective therapies are available for Alzheimer's disease (AD), likely due to its complex etiology that requires a multifactorial therapeutic approach. We have recently shown using transgenic mice that E2 factor 4 (E2F4), a transcription factor that regulates cell quiescence and tissue homeostasis, and controls gene networks affected in AD, represents a good candidate for a multifactorial targeting of AD. Here we show that the expression of a dominant negative form of human E2F4 (hE2F4DN), unable to become phosphorylated in a Thr-conserved motif known to modulate E2F4 activity, is an effective and safe AD multifactorial therapeutic agent. Neuronal expression of hE2F4DN in homozygous 5xFAD (h5xFAD) mice after systemic administration of an AAV.PHP.B-hSyn1.hE2F4DN vector reduced the production and accumulation of Aß in the hippocampus, attenuated reactive astrocytosis and microgliosis, abolished neuronal tetraploidization, and prevented cognitive impairment evaluated by Y-maze and Morris water maze, without triggering side effects. This treatment also reversed other alterations observed in h5xFAD mice such as paw-clasping behavior and body weight loss. Our results indicate that E2F4DN-based gene therapy is a promising therapeutic approach against AD., We thank M.J. Román for her technical help and C. Sánchez-Puelles for her critical reading of the manuscript. This work has been supported by Ministerio de Ciencia, Innovación y Universidades grant RTI2018-095030-B-I00 and a R&D contract between CSIC and Tetraneuron S.L. N.L.S. holds a Torres Quevedo grant from Ministerio de Industria. M.R.L. holds an Industrial Doctorate grant from Ministerio de Economía, Industria y Competitividad.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice

  • López-Sánchez, N.
  • Ramón-Landreau, Morgan
  • Trujillo, Cristina
  • Garrido-García, A.
  • Frade López, José María
Alzheimer’s disease (AD) has a complex etiology, which requires a multifactorial approach for an efficient treatment. We have focused on E2 factor 4 (E2F4), a transcription factor that regulates cell quiescence and tissue homeostasis, controls gene networks affected in AD, and is upregulated in the brains of Alzheimer’s patients and of APP/PS1 and 5xFAD transgenic mice. E2F4 contains an evolutionarily conserved Thr-motif that, when phosphorylated, modulates its activity, thus constituting a potential target for intervention. In this study, we generated a knock-in mouse strain with neuronal expression of a mouse E2F4 variant lacking this Thr-motif (E2F4DN), which was mated with 5xFAD mice. Here, we show that neuronal expression of E2F4DN in 5xFAD mice potentiates a transcriptional program consistent with the attenuation of the immune response and brain homeostasis. This correlates with reduced microgliosis and astrogliosis, modulation of amyloid-β peptide proteostasis, and blocking of neuronal tetraploidization. Moreover, E2F4DN prevents cognitive impairment and body weight loss, a known somatic alteration associated with AD. We also show that our finding is significant for AD, since E2F4 is expressed in cortical neurons from Alzheimer patients in association with Thr-specific phosphorylation, as evidenced by an anti-E2F4/anti-phosphoThr proximity ligation assay. We propose E2F4DN-based gene therapy as a promising multifactorial approach against AD., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work has been supported by grant SAF2015-68488-R funded by Ministerio de Economía y Competitividad, grant RTI2018-095030-B-I00 funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe,” and a R&D contract between CSIC and Tetraneuron. NLS holds a Torres Quevedo grant from Ministerio de Industria. MRL holds an Industrial Doctorate grant from Ministerio de Economía, Industria y Competitividad.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging

  • Ramón-Landreau, Morgan
  • Sánchez-Puelles, Cristina
  • López-Sánchez, Noelia
  • Lozano-Ureña, Anna
  • Llabrés-Mas, Aina M.
  • Frade López, José María
E2F4 was initially described as a transcription factor with a key function in the regulation of cell quiescence. Nevertheless, a number of recent studies have established that E2F4 can also play a relevant role in cell and tissue homeostasis, as well as tissue regeneration. For these non-canonical functions, E2F4 can also act in the cytoplasm, where it is able to interact with many homeostatic and synaptic regulators. Since E2F4 is expressed in the nervous system, it may fulfill a crucial role in brain function and homeostasis, being a promising multifactorial target for neurodegenerative diseases and brain aging. The regulation of E2F4 is complex, as it can be chemically modified through acetylation, from which we present evidence in the brain, as well as methylation, and phosphorylation. The phosphorylation of E2F4 within a conserved threonine motif induces cell cycle re-entry in neurons, while a dominant negative form of E2F4 (E2F4DN), in which the conserved threonines have been substituted by alanines, has been shown to act as a multifactorial therapeutic agent for Alzheimer's disease (AD). We generated transgenic mice neuronally expressing E2F4DN. We have recently shown using this mouse strain that expression of E2F4DN in 5xFAD mice, a known murine model of AD, improved cognitive function, reduced neuronal tetraploidization, and induced a transcriptional program consistent with modulation of amyloid-ß (Aß) peptide proteostasis and brain homeostasis recovery. 5xFAD/E2F4DN mice also showed reduced microgliosis and astrogliosis in both the cerebral cortex and hippocampus at 3-6 months of age. Here, we analyzed the immune response in 1 year-old 5xFAD/E2F4DN mice, concluding that reduced microgliosis and astrogliosis is maintained at this late stage. In addition, the expression of E2F4DN also reduced age-associated microgliosis in wild-type mice, thus stressing its role as a brain homeostatic agent. We conclude that E2F4DN transgenic mice represent a promising tool for the evaluation of E2F4 as a therapeutic target in neuropathology and brain aging., This research was funded by the Ministerio de Economía y Competitividad, grant number RTI2018-095030-B-I00, and the Ministerio de Ciencia e Innovación, grant number PID2021-128473OB-I00, both supported by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”, a R&D contract between CSIC and Tetraneuron, and PTI+ Neuroaging (CSIC). M.R.-L. holds an Industrial Doctorate grant from Ministerio de Economía, Industria y Competitividad. C.S.-P. holds a Torres Quevedo grant from Ministerio de Industria. A.M.L.-M. holds a FPI grant from Ministerio de Ciencia e Innovación.